Northrop Grumman Corporation vs Teladoc Health Inc — how do they compare? Northrop Grumman Corporation trades at $480.06 (market cap $68.83B), while Teladoc Health Inc trades at $5.79 (market cap $1.01B). The key difference: Northrop Grumman Corporation is far larger — about 68.1× Teladoc Health Inc's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Teladoc Health Inc for 39 Days on average.
| NOC | TDOC | |
|---|---|---|
Market Cap | $68.83B | $1.01B |
Volume | 1,081,989 | 4,668,477 |
Sector | Industrials | Health |
52-Week High | $768.02 | $9.72 |
52-Week Low | $473.46 | $4.47 |
Typical Hold Time | 81 Days | 39 Days |
Enterprise Value | $82.81B | $1.27B |
Dividend Yield | 2.04% | — |
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $480.72, up 1.53% on the day, with a bearish technical signal from moving averages but strong fundamentals including a P/E of 15.4 and ROE of 26.96%. Recent quarterly EPS beats and a consensus analyst price target of $600.62 suggest upside potential, though the stock faces headwinds from Boeing's recent $20 billion Navy fighter contract win (Seeking Alpha, 2026-10-02).
The outlook for NOC is supported by a record backlog and defense budget tailwinds, but competitive pressures and execution risks on key programs like the B-21 bomber pose challenges. Analyst sentiment is predominantly bullish with 54% buy ratings, indicating confidence in long-term growth despite near-term volatility.
Teladoc Health (TDOC) trades at $5.77, up 3.78% today but remains near multi-year lows amid ongoing profitability challenges. The stock shows bearish technical signals with mixed earnings performance, having beaten estimates in two of the last three quarters but posting consistent net losses. Recent management changes include the appointment of a new CFO and legal officer as the company focuses on stabilizing its integrated care business while grappling with BetterHelp segment weakness.
While TDOC trades at discounted valuation multiples (P/S 0.4x, P/B 0.77x) and analysts maintain a $8.83 price target, the path to profitability remains uncertain given seven consecutive quarters of negative earnings. The primary investment thesis hinges on the company's ability to monetize its chronic care platform and achieve sustainable free cash flow generation, though investor sentiment remains cautious amid ongoing losses and competitive pressures in virtual healthcare.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →